As Roivant read­ies for a UC clash with Mer­ck, CEO Matt Gline is can­did about keep­ing a com­pet­i­tive edge

Roivant CEO Matt Gline is get­ting ready for a de­vel­op­ment show­down with Mer­ck and its new­ly ac­quired ul­cer­a­tive col­i­tis drug from Prometheus Bio­sciences.

On Thurs­day, Roivant re­leased new Phase IIb da­ta for RVT-3101, the UC pro­gram it ac­quired from Pfiz­er late last year, show­ing that the drug’s ef­fects could be main­tained for up to a year. It’s con­fir­ma­tion of ear­li­er da­ta show­ing suc­cess at 14 weeks — a sta­tis­ti­cal­ly sig­nif­i­cant find­ing, Roivant said in Jan­u­ary.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER